• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ERCC1 rs11615 多态性与基于奥沙利铂的胃肠道癌症化疗临床结局的关系：一项荟萃分析。

Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis.

机构信息

Department of Oncology, The First Hospital of Lanzhou University (The Branch Hospital of Donggang), Lanzhou, Gansu Province, People's Republic of China.

Department of Gastroenterology, The First Hospital of Lanzhou University (The Branch Hospital of Donggang), Lanzhou, Gansu Province, People's Republic of China.

出版信息

Onco Targets Ther. 2015 Mar 16;8:641-8. doi: 10.2147/OTT.S80913. eCollection 2015.

DOI:10.2147/OTT.S80913
PMID:25834456
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4365759/
Abstract

PURPOSE

The relationship between the excision repair cross-complementing 1 (ERCC1) rs11615 polymorphism (C/T) and responses to oxaliplatin-based chemotherapy for gastric cancer (GC) and colorectal cancer (CRC) patients is controversial. Therefore, we performed a meta-analysis to assess this relationship.

METHOD

Relevant studies were retrieved by searching the PubMed database. A systematic review and meta-analysis was performed to evaluate the predictive value of the ERCC1 rs11615 polymorphism for the clinical outcomes of GC and CRC patients receiving oxaliplatin-based chemotherapy. Therapeutic response to chemotherapy, progression-free survival (PFS), and overall survival (OS) were analyzed.

RESULTS

A total of 22 studies were included in this meta-analysis, including 1,242 cases of GC and 1,772 cases of CRC. For the ERCC1 rs11615 polymorphism, the T allele was associated with a reduced response to chemotherapy in Asians and GC patients (P<0.05). On the other hand, the T allele was associated with a significant increase in the risk for shorter PFS and OS in all patients (PFS: hazard ratio [HR] =1.22, P<0.001, 95% confidence interval [CI] =0.93-1.51 and OS: HR =1.12, P<0.001, 95% CI =0.85-1.40).

CONCLUSION

The ERCC1 rs11615 polymorphism was closely associated with the clinical outcomes of GC and CRC patients treated with oxaliplatin-based chemotherapy.

摘要

目的

切除修复交叉互补基因 1（ERCC1）rs11615 多态性（C/T）与胃癌（GC）和结直肠癌（CRC）患者对奥沙利铂为基础的化疗反应之间的关系存在争议。因此，我们进行了一项荟萃分析来评估这种关系。

方法

通过检索 PubMed 数据库检索相关研究。系统评价和荟萃分析评估了 ERCC1 rs11615 多态性对接受奥沙利铂为基础的化疗的 GC 和 CRC 患者临床结局的预测价值。分析了化疗的治疗反应、无进展生存期（PFS）和总生存期（OS）。

结果

这项荟萃分析共纳入 22 项研究，包括 1242 例 GC 和 1772 例 CRC。对于 ERCC1 rs11615 多态性，T 等位基因与亚洲人和 GC 患者对化疗的反应降低相关（P<0.05）。另一方面，T 等位基因与所有患者的较短 PFS 和 OS 风险显著增加相关（PFS：风险比[HR] =1.22，P<0.001，95%置信区间[CI] =0.93-1.51 和 OS：HR =1.12，P<0.001，95% CI =0.85-1.40）。

结论

ERCC1 rs11615 多态性与接受奥沙利铂为基础的化疗的 GC 和 CRC 患者的临床结局密切相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/674a/4365759/b3d7d71f3bfa/ott-8-641Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/674a/4365759/954ffb22c8a9/ott-8-641Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/674a/4365759/96a04bf944e9/ott-8-641Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/674a/4365759/b3d7d71f3bfa/ott-8-641Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/674a/4365759/954ffb22c8a9/ott-8-641Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/674a/4365759/96a04bf944e9/ott-8-641Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/674a/4365759/b3d7d71f3bfa/ott-8-641Fig3.jpg

相似文献

1
Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis.ERCC1 rs11615 多态性与基于奥沙利铂的胃肠道癌症化疗临床结局的关系：一项荟萃分析。
Onco Targets Ther. 2015 Mar 16;8:641-8. doi: 10.2147/OTT.S80913. eCollection 2015.
2
The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.ERCC1基因C118T多态性可预测接受奥沙利铂化疗的结直肠癌患者的临床结局：一项基于22项研究的荟萃分析
Asian Pac J Cancer Prev. 2014;15(19):8383-90. doi: 10.7314/apjcp.2014.15.19.8383.
3
ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.ERCC1 和 ERCC2 多态性可预测胃癌和结直肠癌奥沙利铂为基础的化疗的临床结局：系统评价和荟萃分析。
Clin Cancer Res. 2011 Mar 15;17(6):1632-40. doi: 10.1158/1078-0432.CCR-10-2169. Epub 2011 Jan 28.
4
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin.切除修复交叉互补基因1（ERCC1）的诱导动力学和多态性是接受奥沙利铂治疗的结直肠癌患者预后较差的标志物。
Oncotarget. 2019 Sep 17;10(53):5510-5522. doi: 10.18632/oncotarget.27140.
5
[Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].[ERCC1基因多态性与上皮性卵巢癌患者铂类化疗疗效]
Zhonghua Fu Chan Ke Za Zhi. 2013 Nov;48(11):847-52.
6
Association between ERCC1 Gene Polymorphism (rs11615) and Colorectal Cancer Susceptibility: A Meta-Analysis of Medical Image Fusion and Safety Applications.ERCC1 基因多态性（rs11615）与结直肠癌易感性的关系：医学图像融合与安全应用的荟萃分析。
Comput Math Methods Med. 2022 Oct 14;2022:9988513. doi: 10.1155/2022/9988513. eCollection 2022.
7
A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy.一项荟萃分析确定ERCC1基因多态性是患者对放化疗治疗反应更好的预测指标。
Cancer Chemother Pharmacol. 2016 Jun;77(6):1183-91. doi: 10.1007/s00280-016-3015-9. Epub 2016 Apr 21.
8
The Contribution of Excision Repair Cross-complementing Group 1 Genotypes to Colorectal Cancer Susceptibility in Taiwan.切除修复交叉互补基因1基因型对台湾地区结直肠癌易感性的影响
Anticancer Res. 2017 May;37(5):2307-2313. doi: 10.21873/anticanres.11568.
9
Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers.伊朗结直肠癌和胃癌患者中ERCC1基因多态性与铂类化疗反应的关系研究
Iran J Pharm Res. 2019 Fall;18(4):2163-2171. doi: 10.22037/ijpr.2019.1100827.
10
The XPD Lys751Gln polymorphism has predictive value in colorectal cancer patients receiving oxaliplatin-based chemotherapy: a systemic review and meta-analysis.XPD Lys751Gln多态性在接受奥沙利铂化疗的结直肠癌患者中具有预测价值：一项系统评价和荟萃分析。
Asian Pac J Cancer Prev. 2014;15(22):9699-706. doi: 10.7314/apjcp.2014.15.22.9699.

引用本文的文献

1
Updates on global epidemiology, risk and prognostic factors of gastric cancer.全球胃癌流行病学、风险和预后因素的最新研究进展。
World J Gastroenterol. 2023 Apr 28;29(16):2452-2468. doi: 10.3748/wjg.v29.i16.2452.
2
The critical role of circular RNAs in drug resistance in gastrointestinal cancers.环状RNA在胃肠道癌症耐药中的关键作用。
Med Oncol. 2023 Mar 14;40(4):116. doi: 10.1007/s12032-023-01980-4.
3
The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?胆汁酸膜受体 TGR5 在癌症中的作用：是敌是友？

本文引用的文献

1
ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy.ERCC1、XRCC1 和 GSTP1 单核苷酸多态性与接受奥沙利铂为基础的辅助化疗的结肠癌患者生存的关系。
J Cancer. 2014 May 2;5(6):425-32. doi: 10.7150/jca.8594. eCollection 2014.
2
Molecular mechanism of global genome nucleotide excision repair.全球基因组核苷酸切除修复的分子机制。
Acta Naturae. 2014 Jan;6(1):23-34.
3
Polymorphisms in the insulin-like growth factor axis are associated with gastrointestinal cancer.
Molecules. 2022 Aug 19;27(16):5292. doi: 10.3390/molecules27165292.
4
Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review.DNA修复途径中的基因变异作为预测结直肠癌腹膜转移患者腹腔化疗治疗结果的潜在生物标志物：一项系统综述
Front Pharmacol. 2020 Oct 6;11:577968. doi: 10.3389/fphar.2020.577968. eCollection 2020.
5
ERCC overexpression associated with a poor response of cT4b colorectal cancer with FOLFOX-based neoadjuvant concurrent chemoradiation.ERCC过表达与基于FOLFOX方案的新辅助同步放化疗的cT4b期结直肠癌疗效不佳相关。
Oncol Lett. 2020 Nov;20(5):212. doi: 10.3892/ol.2020.12075. Epub 2020 Sep 8.
6
Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma.胃腺癌耐药机制的分子基础
Cancers (Basel). 2020 Jul 30;12(8):2116. doi: 10.3390/cancers12082116.
7
Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.DNA 修复基因变异与结直肠癌的关联：风险、毒性和生存。
BMC Cancer. 2020 May 12;20(1):409. doi: 10.1186/s12885-020-06924-z.
8
Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer.结直肠癌的药物基因组学、生物标志物网络和等位基因频率。
Pharmacogenomics J. 2020 Feb;20(1):136-158. doi: 10.1038/s41397-019-0102-4. Epub 2019 Oct 15.
9
and but not single nucleotide polymorphisms correlate with response to chemotherapy in endometrial carcinoma.并且单核苷酸多态性与子宫内膜癌化疗反应不相关。
Onco Targets Ther. 2016 Nov 14;9:7019-7028. doi: 10.2147/OTT.S110976. eCollection 2016.
10
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.ERCC1表达影响接受FOLFIRINOX治疗的转移性胰腺癌的预后：单机构分析。
Oncotarget. 2016 Jun 7;7(23):35159-68. doi: 10.18632/oncotarget.9063.
胰岛素样生长因子轴的多态性与胃肠道癌症相关。
PLoS One. 2014 Mar 7;9(3):e90916. doi: 10.1371/journal.pone.0090916. eCollection 2014.
4
Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study.吉非替尼联合塞来昔布治疗晚期转移性胃肠肿瘤的可行性研究。
J Gastrointest Oncol. 2014 Feb;5(1):57-66. doi: 10.3978/j.issn.2078-6891.2013.056.
5
Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses.评价发表的系统评价和荟萃分析的质量对首选报告项目的系统评价和荟萃分析 (PRISMA) 声明的认可。
PLoS One. 2013 Dec 26;8(12):e83138. doi: 10.1371/journal.pone.0083138. eCollection 2013.
6
Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.ERCC1和ERCC4基因多态性对接受基于FOLFOX方案化疗的胃癌患者预后反应的影响。
Tumour Biol. 2014 Apr;35(4):2941-8. doi: 10.1007/s13277-013-1378-7. Epub 2013 Dec 8.
7
Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin.切除修复交叉互补基因 1（ERCC1）C118T 单核苷酸多态性不影响细胞对奥沙利铂的反应。
Mutat Res. 2014 Jan;759:37-44. doi: 10.1016/j.mrfmmm.2013.11.001. Epub 2013 Nov 9.
8
Polymorphisms of , and -3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients.、和-3'非翻译区的多态性与结直肠癌患者接受mFOLFOX6治疗的临床结局相关。
Oncol Lett. 2013 Sep;6(3):648-654. doi: 10.3892/ol.2013.1467. Epub 2013 Jul 15.
9
Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.青藏高原人群中切除修复交叉互补组1密码子118多态性、微小核糖核酸及蛋白表达与晚期胃癌一线FOLFOX-4治疗临床结局的关系
J Cancer Res Ther. 2013 Jul-Sep;9(3):410-5. doi: 10.4103/0973-1482.119319.
10
ERCC1 and ERCC2 variants predict survival in gastric cancer patients.ERCC1 和 ERCC2 变体可预测胃癌患者的生存情况。
PLoS One. 2013 Sep 2;8(9):e71994. doi: 10.1371/journal.pone.0071994. eCollection 2013.